0001104659-24-010262.txt : 20240202 0001104659-24-010262.hdr.sgml : 20240202 20240202200514 ACCESSION NUMBER: 0001104659-24-010262 CONFORMED SUBMISSION TYPE: 5 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oliviero James F III CENTRAL INDEX KEY: 0001434718 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 5 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38128 FILM NUMBER: 24593574 MAIL ADDRESS: STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC. STREET 2: 750 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 5 1 tm245141-3_5seq1.xml OWNERSHIP DOCUMENT X0508 5 2023-12-31 0 0 1 0001651407 Checkpoint Therapeutics, Inc. CKPT 0001434718 Oliviero James F III 95 SAWYER RD, SUITE 110 WALTHAM MA 02453 1 1 0 0 CEO, President and Director 0 Common Stock 2023-02-24 5 G 0 42000 0 D 381580 D Common Stock 2023-08-16 4 G 0 L 12510 0 D 381580 D On February 24, 2023, 42,000 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. Includes shares of restricted common stock, which vest over various time periods. On August 16, 2023, 12,510 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. /s/ James F. Oliviero, III 2024-02-02